| Trial ID: | L5412 |
| Source ID: | NCT04521049
|
| Associated Drug: |
Saxagliptin 5mg
|
| Title: |
Tubular Markers in Response to Saxagliptin Therapy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Saxagliptin 5mg
|
| Outcome Measures: |
Primary: to measure renal effect of saxagliptin on tubular markers, the rate of change of uNGAL and u LFABP markers would be estimated across the two time points after saxagliptin treatment ., 3 months|to measure effect of saxagliptin on renal on albuminuria, the rate of change of UACR would be measured across the two time points after saxagliptin treatment, 3 months|to classify renal responders to saxagliptin using tubular markers, patients would be classified into high risk and low risk patients according to their marker levels, 3 months |
|
| Sponsor/Collaborators: |
Sponsor: Beni-Suef University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-03-01
|
| Completion Date: |
2020-04-01
|
| Results First Posted: |
|
| Last Update Posted: |
2020-08-20
|
| Locations: |
Faculty of Pharmacy, Al Qāhirah Al Jadīdah, 0004, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04521049
|
